| 1,367 | 103 | 42 |
| 下载次数 | 被引频次 | 阅读次数 |
目的了解不同乙型肝炎(乙肝)病毒(Hepatitis B virus,HBV)流行地区的原发性肝癌(Primary liver cancer,PLC)患病和HBV感染情况,为乙肝防控及乙肝疫苗(Hepatitis B vaccine,Hep B)免疫策略的优化提供依据。方法在全国6个省份各选择1个监测地区搜索PLC病例,开展随访调查,收集血清样本进行HBV表面抗原(HBs Ag)检测,分析PLC患病率和HBs Ag阳性率。结果 2012-2015年6个监测地区共收集PLC病例3 262例。PLC年均患病率各监测地区在8.71/10万-64.48/10万之间;男、女性分别为13.58/10万、4.25/10万;<70岁人群随着年龄增长呈上升趋势(趋势x2=4 451.26,P=0.000)。在PLC病例中,男、女性HBs Ag阳性率分别为71.18%、65.83%(x2=6.31,P=0.012);年龄别HBs Ag阳性率为65.21%-72.59%(x2=9.01,P=0.173);民族别HBs Ag阳性率为41.67%-83.90%(x2=85.31,P=0.000);各监测地区HBs Ag阳性率为58.56%-85.40%(x2=90.59,P=0.000)。结论监测地区PLC患病率随年龄增长而升高,且PLC病例的HBs Ag阳性率高。建议大年龄HBV感染者定期进行肝病筛查。
Abstract：Objective To explore the prevalence of hepatitis B virus(HBV) infections among primary liver cancer(PLC) patients in six pilot regions with differing HBV epidemiology,and to provide evidence for optimizing hepatitis B prevention and hepatitis B vaccine(Hep B) immunization strategies. Methods We choose one county in each of six provinces to identify PLC cases for a follow-up survey and to collect serum samples to detect HBV surface antigen(HBs Ag). We analyzed PLC prevalence and HBs Ag positivity rates. Results A total of 3 262 PLC cases were identified during 2012-2015 in the six pilot regions. The average annual prevalence of PLC ranged from 8. 71 to 64. 48 per 100 000 population by region,with rates of 13. 58 per 100 000 for males and 4. 25 per 100 000 for females,rising with increasing age among the < 70 year-olds(trend x2= 4 451. 26,P = 0. 000). Among PLC cases,the positivity rates of HBs Ag were 71. 18% for males and 65. 83% for females(x2= 6. 31,P = 0. 012),ranging from65. 21% to 72. 59% by age(x2= 9. 01,P = 0. 173),from 41. 67% to 83. 90% by race/ethnicity(x2=85. 31,P = 0. 000),and from 58. 56% to 85. 40% by region(x2= 90. 59,P = 0. 000). Conclusions The prevalence of PLC rose with increasing age,and the positivity rate of HBs Ag was high among PLC cases in six pilot regions. Older patients with chronic HBV infection should be screened regularly for liver disease.
[1]吴孟超.原发性肝癌在中国的治疗和研究现状[J].成都医学院学报,2012,7(2):161-162.WU MC.The current development in treatment and research for primary liver cancer of China[J].Journal of Chengdu Medical College,2012,7(2):161-162.
[2]任建松,乔友林.原发性肝癌危险因素与预防研究进展[J].中国肿瘤,2008,17(4):293-296.REN JS,QIAO YL.Recent advance in risk factor and prevention for primary liver cancer[J].China Cancer,2008,17(4):293-296.
[3]沈小雷,王海捷,施启生,等.乙型肝炎病毒感染与肝癌关系的26年前瞻性定群观察[J].江苏预防医学,2015,26(5):11-13.SHEN XL,WANG HJ,SHI QS,et al.Analysis of relationship between hepatitis B virus infection and primary liver cancer by a 26-year prospective cohort study in Qidong of Jiangsu province[J].Jiangsu Journal of Preventive Medicine,2015,26(5):11-13.
[4]鲁笑欣,张春燕,黄天壬,等.2004-2013年广西6201例原发性肝癌患者乙肝和丙肝病毒感染情况分析[J].山东医药,2015,55(14):35-37.LU XX,ZHANG CY,HUANG TR,et al.Analysis of hepatitis B and hepatitis C virus infection in 6201 patients with primary liver cancer in Guangxi during 2004-2013 years[J].Shandong Medical Journal,2015,55(14):35-37.
[5]CUI FQ,SHEN LP,LI L,et al.Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy,China[J].Emerging Infectious Diseases,2017,23(5):765-772.
[6]沈立萍,龚晓红,王锋,等.乙型肝炎疫苗长期免疫效果评价及免疫持久性分析[J].中华微生物与免疫学杂志,2013,33(1):6-10.SHEN LP,GONG XH,WANG F,et al.Study on long-term efficacy and duration of hepatitis B vaccine in China[J].Chinese Journal of Microbiology and Immunology,2013,33(1):6-10.
[7]俞顺章,任宏,吴春晓,等.上海市乙型肝炎疫苗接种预防乙型肝炎和肝癌回顾与展望[J].上海预防医学,2015,27(7):369-373,391.YU SZ,REN H,WU CX,et al.Review and prospect of hepatitis B vaccination for prevention of hepatitis B and liver cancer in Shanghai[J].Shanghai Journal of Preventive Medicine,2015,27(7):369-373,391.
[8]NIU JJ,LIN Y,GUO Z,et al.The epidemiological investigation on the risk factors of hepatocellular carcinoma[J].Observational Study,2016,95(6):1-6.
[9]QU C,CHEN T,FAN C,et al.Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year followup of the Qidong hepatitis B intervention study:a cluster randomized controlled trial[J].Plo S Med,2014,11(12):e1001774.
[10]ZHANG XF,LIU XM,WEI T,et al.Clinical characteristics and outcome of hepatocellular carcinoma in children and adolescents[J].Pediatric Surgery International,2013,29(8):763-770.
[11]陈陶阳,孙燕,吴燕,等.HBs Ag携带及肝癌家族史与原发性肝癌发病年龄的相关性分析[J].国际肿瘤学杂志,2015,42(2):324-326.CHEN TY,SUN Y,WU Y,et al.Analysis of association of hepatitis B virus infection and family history of hepatocellular carcinoma with age at primary liver cancer[J].J Int Oncol,2015,42(2):324-326.
[12]舒敏,沈福杰,毛宇明,等.1992—2013年上海市黄浦区原发性肝细胞癌流行病学研究[J].职业与健康,2015,31(20):2802-2804,2807.SHU M,SHEN FJ,MAO YM,et al.Epidemiological study on hepatocellular carcinoma in Huangpu district of Shanghai from1992-2013[J].Occupation and Health,2015,31(20):2802-2804,2807.
基本信息:
DOI：10.19914/j.cjvi.2018.02.003
中图分类号:R512.62;R735.7
引用信息:
[1]张爽,王锋,孟庆玲,等.原发性肝癌患者流行病学与乙型肝炎病毒感染调查[J].中国疫苗和免疫,2018,24(02):133-136+151.DOI:10.19914/j.cjvi.2018.02.003.
基金信息:
国家科技部“十二五”重大科技专项(2012ZX10002001)
2018-03-06
2018-03-06
2018-03-06